Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|
p-value | HR [95%CI] | p-value | HR [95%CI] | ||
Age | < 0.001 | 1.038 [ 1.027–1.049] | < 0.001 | 1.032 [1.017—1.048] | |
Gender (female vs. male) | < 0.001 | 0.491 [0.409–0.591] | 0.447 | 0.884 [0.643—1.215] | |
Smoking History (+ vs. –) | < 0.001 | 2.108 [1.741–2.554] | 0.172 | 1.265 [0.903—1.771] | |
Operation time | < 0.001 | 1.003 [1.002–1.004] | 0.016 | 1.002 [1.001–1.004] | |
Invasion | |||||
Lymphatic vessel invasion (+ vs. –) | < 0.001 | 3.056 [2.533–3.685] | 0.378 | 1.140 [0.852—1.525] | |
Vascular invasion (+ vs. –) | < 0.001 | 3.125 [2.597–3.759] | 0.015 | 1.417 [1.071—1.874] | |
Pleural invasion (+ vs. –) | < 0.001 | 2.519 [2.113–3.004] | 0.518 | 1.096 [0.830—1.447] | |
Adenocarcinoma predominance | |||||
AIS + MIA | control | control | |||
Lepidic | 0.198 | 1.360[0.852–2.172] | 0.998 | 0.999 [0.455—2.197] | |
Acinar + Papillary + Variants | < .001 | 2.600 [1.745–3.876] | 0.380 | 1.366 [0.681—2.739] | |
Solid + Micropapillary | < .001 | 5.178 [3.355–7.991] | 0.041 | 2.182 [1.031—4.617] | |
EGFR status (+ vs. –) | < 0.001 | 0.551 [0.439–0.692] | 0.050 | 0.762 [0.581—1.000] | |
Adjuvant chemotherapy (+ vs. –) | < 0.001 | 0.645 [0.769–0.541] | 0.034 | 0.740 [0.561—0.977] | |
Clinical stage | |||||
Stage IA | control | control | |||
Stage IB | < 0.001 | 1.778[1.445—2.188] | 0.796 | 1.041 [0.767—1.414] | |
Stage IIA | < 0.001 | 3.032 [2.295—4.005] | 0.358 | 1.204 [0.810—1.790] | |
Stage IIB | < 0.001 | 2.853 [1.911—4.259] | 0.701 | 0.882 [0.466—1.671] | |
Stage IIIA | < 0.001 | 4.581 [3.347—6.270] | 0.938 | 0.981 [0.602—1.597] | |
Pathological stage | |||||
Stage IA | control | control | |||
Stage IB | < 0.001 | 2.038 [1.578—2.631] | 0.026 | 1.640 [1.062—2.534] | |
Stage IIA | < 0.001 | 4.513 [3.419—5.957] | < 0.001 | 2.588 [1.622—4.131] | |
Stage IIB | < 0.001 | 4.961 [3.440—7.154] | 0.027 | 2.063 [1.087—3.915] | |
Stage IIIA | < 0.001 | 6.695 [5.244—8.548] | < 0.001 | 4.112 [2.559—6.606] |